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While malaria research has traditionally been strong in Europe, targeted and sustained support for cooperative
malaria research at EU level, namely through the EU’s 6th and 7th Framework Programmes for research and
technological development, FP6 (2002-2006) and FP7 (2007-2013), has boosted both impact and visibility of
European malaria research. Most of the European malaria research community is now organized under a number
of comprehensive and complementary research networks and projects, assembled around four key areas:
(1) fundamental research on the malaria parasite and the disease, (2) development of new malaria drugs,
(3) research and development of a malaria vaccine, and (4) research to control the malaria-transmitting mosquito
vector. Considerable efforts were undertaken to ensure adequate participation of research groups from disease-
endemic countries, in particular from Africa, with the long-term aim to strengthen cooperative links and research
capacities in these countries. The concept of organizing European research through major strategic projects to
form a “European Research Area” (ERA) was originally developed in the preparation of FP6, and ERA formation has
now turned into a major EU policy objective explicitly inscribed into the Lisbon Treaty. EU-funded malaria research
may serve as a showcase to demonstrate how ERA formation can successfully be implemented in a given area of
science when several surrounding parameters converge to support implementation of this strategic concept: timely
coincidence of political stimuli, responsive programming, a clearly defined - and well confined - area of research,
and the readiness of the targeted research community who is well familiar with transnational cooperation at EU
level. Major EU-funded malaria projects have evolved into thematic and organizational platforms that can
collaborate with other global players. Europe may thus contribute more, and better, to addressing the global
research agenda for malaria.
The global burden of malaria
According to the World Health Organization (WHO),
there were in 2008 an estimated 247 million malaria
cases among more than 3 billion people at risk, causing
nearly one million deaths (even much more according
to other estimates), mostly of children under 5 years
and pregnant women [1,2]. Malaria is a vector-borne
disease transmitted to humans through the bite of
female Anopheles mosquitoes. The most lethal of the
species of malaria parasites that infect humans is Plas-
modium falciparum, which is common in sub-Saharan
Africa but also present in tropical and subtropical areas
of Central and South America, Asia and in the Middle
East [2]. Analysis of the relationship between malaria
burden and socio-economic factors reveals that the glo-
bal distribution of malaria shows a striking correlation
with the respective per-capita gross domestic product
(GPD), with lower rates of economic growth in malaria-
endemic countries [3]. In light of the United Nations’
Millenium Development goals, global malaria control
efforts have been challenged by the Bill and Melinda
Gates Foundation (BMGF) together with WHO’s Global
Malaria Action Plan (GMAP), aiming to totally eradicate
malaria, or as a short-term goal, to eliminate malaria on
a country-by-country basis [4].
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Malaria research in Europe has always been strong, his-
torically being driven by the need to cope with tropical
diseases encountered in the former colonies of European
nations [5-7]. Furthermore, until eradication campaigns
were successfully conducted in the first half of the 20th
century, malaria was endemic in large parts of southern
Europe, notably in Italy (where the name “ mal aire”
was coined to designate the disease), but also in south-
ern France, Greece and the whole of the Balkan region
[8,9]. Typically, malaria research in Europe was, and to
a large extent still is, conducted either in national
research institutions dedicated to tropical medicine (e.g.
Schools of, or Institutes for, Tropical Medicine, Hygiene,
Parasitology etc), or in a scatter of specialized university
hospitals where tropical diseases had become a major
focus of clinical research. Former European colonial
powers also set up dedicated clinical research institu-
tions located in their former malaria-endemic colonies,
e.g. the British MRC Unit in The Gambia or the, origin-
ally French, Institut Pasteur in Senegal. In addition, a
number of both small and larger European pharmaceuti-
cal companies have continuously been active in the area
of malaria drugs and vaccines research [10].
European Union Funding for Malaria Research:
from FP5 to FP7
Building on European Member States’ national invest-
ments in malaria research and reflecting the EU’sp o l i t i -
cal commitment to contribute to the global development
goals from research side [11], malaria research has
received rather sustained funding under the EU’s recent
research framework programmes. In the 5
th Framework
Programme (FP5, 1998-2002), under the “International
Co-operation (INCO)” and the “Control of Infectious
Diseases” sections, around € 35 million were spent on a
total of ~ 30 separate malaria co-operation projects (with
a mean volume of around € 1 million per project) [12]. A
high-level round table conference on major communic-
able diseases in Brussels stressed again in the year 2000
the importance of research to combat the three big killer
diseases. The EU responded to this political call in 2001
by setting up the first comprehensive “Programme of
Action: accelerated action on HIV/AIDS, malaria and
tuberculosis in the context of poverty reduction” [11],
which comprised a strong section on research support.
This coincided with the new structural approach pro-
posed by the European Commission for the 6
th Frame-
work Programme (FP6, 2002-2006), aimed at forming a
rationally structured, open and sustained “European
Research Area” (ERA) [13]. In this context, not only were
some of the thematic areas re-examined for more tar-
geted EU research support, but also the funding tools to
address these research areas under FP6 were revised to
become larger and more structurally organized projects
[14]. In the course of these processes, the “Three Big
Poverty-related Diseases” (HIV/AIDS, malaria and tuber-
culosis) acquired a clearly defined thematic, organiza-
tional and budgetary focus under FP6, a novelty under
the EU research framework programmes. The ambition
under FP6 was to overcome the fragmentation of impor-
tant areas of research in Europe and to move towards a
more structured, but open “European Research Area”
(ERA). In practical terms, FP6 was designed to address
key thematic areas through strategically placed, large-
scale European research projects and networks,
assembled around major scientific objectives and aiming
to structure the respective field of research. The currently
on-going FP7 programme builds in essence on the FP6
concept, still placing emphasis on large, high impact,
and/or ERA-structuring projects [15]. A research focus
on HIV/AIDS, malaria and tuberculosis, has been main-
tained also under FP7.
Implementing the European Research Area (ERA)
in the field of malaria research
A consultation of the science community, held at the
beginning of FP6, identified topical research areas for
FP6 as well as appropriate funding schemes to address
them. In the case of malaria research, this consultation
yielded very straightforward and clear recommendations:
(1) Fundamental malaria researchers should organize
themselves in a large and comprehensive “Network
of Excellence";
(2) European efforts to discover and develop new
anti-malarial medicines should be grouped and man-
aged under the umbrella of an “Integrated Project”
for new malaria drugs; and
(3) European research groups aiming to prevent
malaria by developing a vaccine should organize
themselves under a larger “Integrated Project” on
malaria vaccines.
Funding for Integrated Projects and Networks of
Excellence under FP6 normally ranged between € 10
and 20 million each, which constituted a significant rise
in project funding as compared with previous frame-
work programmes, but which was still insufficient to
allow for clinical testing of potential new drugs or vac-
cines in disease-endemic settings, principally in Africa.
Thus, in order to provide EU support also for the costly
and logistically demanding clinical testing part of the
product development pipeline, namely for phase 2 and
phase 3 clinical efficacy studies in Africa, a major new
initiative, sourced by € 200 million of FP6 funds and
matching investments from Member States, was
launched in 2003, the “European and Developing
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remit of EDCTP is to test new interventions to confront
HIV/AIDS, malaria and tuberculosis in clinical trials in
Africa, and here a significant proportion of EDCTP
funds goes towards testing new drugs and vaccines for
malaria, next to new interventions for HIV and tubercu-
losis. Figure 1 depicts how the strategic recommenda-
tions for malaria research at the start of FP6 between
2003 and 2006 were translated into corresponding
EU-funded cooperative networks.
(1) “BioMalPar”, a Network of Excellence coordi-
nated by Institut Pasteur in Paris, conducting funda-
mental research on “Biology and pathology of the
malaria parasite” [17];
(2) “ANTIMAL”, an Integrated Project coordinated
by the Liverpool School of Tropical Medicine, on
the “Development of New Drugs for the Treatment
of Malaria” [18], and
(3) “EMVDA”,i . e .t h e“European Malaria Vaccine
Development Association” [19], an Integrated Project
originally coordinated by the “European Malaria Vac-
cine Initiative (EMVI)”, at the time hosted by the Sta-
tens Serum Institute in Copenhagen. EMVI has by
now acquired its own legal personality, such that
EMVDA since the end of 2009 is now coordinated by
EMVI’s successor organization named European Vac-
cine Initiative (EVI) which is based in Heidelberg.
Figure 1 also highlights some key features and data on
each of the three FP6 cornerstone projects. It should be
noted that these three major structural projects were
throughout the lifetime of FP6 complemented by a scat-
ter of small scale, innovative malaria projects, and also
by other not disease specific research projects looking at
cross-cutting issues. The total of EU funding committed
to malaria research under FP6, is displayed in Figure 2:
approximately € 65 million were directly allocated to
malaria projects following FP6 calls, while additional
approximately € 35 million (up to 2010), were invested
in malaria-relevant intervention trials and research capa-
cities in Africa, supported by EDCTP.
Figure 1 FP6-funded research projects structuring the European Research Area (ERA) in the field of malaria.
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under FP7
The on-going 7
th EU Framework Programme for
research and technological development (2007-2013),
again features malaria as an identified target area for
research support, as part of research on “Infectious Dis-
eases”. Under the first four calls of FP7 thematic sub-
areas of malaria research that had not previously been
tackled under FP6, were taken up, largely following the
FP6 strategy to create large “ERA structuring” malaria
projects which can usefully contribute to global research
needs in the respective area. Support for malaria basic
research is continued under the FP7 Network of Excel-
lence (NoE) EVIMalaR, which aims to further integrate
the participating institutions towards forming a virtual
“European Malaria Research Institute” [20].
O n em a j o rm a l a r i ar e s e a r c hf o c u st a k e nu pu n d e r
FP7 concerns research to control malaria transmission
by targeting the mosquito vector. An infrastructure
project (INFRAVEC) has been established to facilitate
genetic modification of the malaria mosquito vector
(to make it refractory to the transmission of malaria),
and to support rearing and fitness testing of modified
mosquitoes in a confined-release facility [21]. This
infrastructure effort is complemented by a major
transnational research project on new and improved
interventions for vector control, called AVecNet, coor-
dinated by Liverpool School of Tropical Medicine,
which supports a network of eight European and five
African institutions and two European insecticide-
producing companies, with EU funding of € 12 million.
As yet about € 80 million in total have been com-
mitted for malaria research in FP7 (Figure 3) including
other areas like pregnancy malaria or basic research
topics, that were tackled not only under the FP7
Health research, but also by complementary projects
under the FP7 Ideas and People programmes. Future
calls under the remaining time of FP7 could address
implementation research to evaluate best use of exist-
ing and new malaria control interventions in the
context of local health systems conditions, including
the development and best use of diagnostics (Figure 4).
Strategic achievements of malaria research under
the EU’s framework programmes - and lessons
learned
Which particular achievements have come out from this,
at the time of the start of FP6, new strategic approach,
namely to organize European, and African malaria
researchers around key topical themes under few large
EU-funded project frameworks, that to a good extent
are managed by the researchers themselves? Clearly, the
administrative burden for the scientists, and in particu-
lar for the coordinators, to manage such large EU pro-
jects, is significant. Yet, in return, the concept has
allowed specific research agendas to be driven by those
who are most knowledgeable in the field, i.e. the compe-
tent institutions and researchers in the respective fields,
with guidance given by independent external expert
committees, and by the funding organization, the EU’s
Directorate-General for Research, who has to ensure
that tax payers money is properly spent and accounted
for. But there are other assets and advantages that are
possible only within the framework of a large strategic
umbrella project on the respective subtheme of malaria
research: (1) comparability of data sets for several
sub-projects e.g. on new drugs or vaccine candidates,
allowing for prioritization or de-selection of product
candidates, (2) critical mass of research candidates justi-
fies the assembly of comprehensive preclinical assay
modules as a central project facility, e.g. comprising har-
monized pre-clinical assays and animal models, (3) large
EU projects, each involving most of the key European
players in the respective thematic areas, can more com-
petently participate in larger international initiatives,
(4) within one, and across several, of these larger EU
projects, synergies can be exploited e.g. concerning
essential horizontal activities, such as joint training
schemes. The following examples, extracted from the
major FP6- and FP7-funded malaria projects, may more
concretely demonstrate these conceptual gains.
Figure 2 EU-funded malaria research under FP6 (2002 - 2006),
split by thematic subareas.
Figure 3 EU-funded malaria research under FP7 (2007-2013, up
to 2010 budget), split by thematic subareas.
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MAL (Figure 1), 18 sub-projects dealing with different
drugs candidates, were grouped under one FP6 “Inte-
grated Project” (IP). While initially all sub-projects
received research support, candidate drugs were then
continuously scrutinized through comparative evaluation
exercises, by an industry-type, competent group of drug
developers external to the project, who on the basis of
comparable data packages recommended candidate drugs
to be further developed, or to be terminated. These
recommendations taken up by the project’s joint manage-
ment, thus led to a de-selection of drugs candidates, such
that eventually only three of these go into human phase 1
trials. Evidently, this comparative de-selection requires
an agreed common project framework, provided through
the FP6-funded project structure.
Similarly, the FP6 malaria vaccine project EMVDA has
regrouped several European malaria vaccine approaches
under one project framework (Figure 1). EMVDA estab-
lishes a core module of standardized preclinical assays
and models (with standardization still forming part of
the project’s work programme), in order to allow for
comparability of diverse vaccine candidates, before these
enter into costly product and clinical development
phases. New vaccine candidates were invited to join the
project through an open call, however, prior to allocat-
ing funds to GMP production and human trials, these
new candidates had to pass through EMVDA’sa g r e e d
preclinical assay package, and produce convincing data
to support further investments.
The FP6 malaria basic research network BioMalPar
(Figure 1) has, since 2004, developed into a cornerstone of
EU malaria research, and has under FP7 been followed by
a new network called EVIMalaR. Apart from an impressive
output of about 500 original papers, important structural
gains resulted from this sustained EU effort in the field of
basic research on malaria: the creation of an open annual
malaria conference in Europe (BiomalPar conference) that
has become a key event in fundamental research in
malaria; a strongly integrative European Malaria Graduate
School, operated through EMBL in Heidelberg, with cen-
tral training modules and always linking at least two part-
ner groups on a jointly conducted PhD project; a malaria
research protocol book, generated jointly between the
American ATCC-based MR4 center and BioMalPar; a
popular web-based interactive malaria research teaching
tool provided on the BioMalPar website, maintained by
the Hebrew University in Jerusalem.
Figure 4 Large FP6- and FP7-supported malaria projects structuring ERA.
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full partners a good number of research groups from
malaria-endemic countries, mainly from Africa (Figure 1),
thus demonstrating the outreach feature of an “Open
European Research Area” as called for since the inception
of the ERA strategy [13,22]. Other indicators for
enhanced visibility and impact of the European malaria
consortia at international level: BiomalPar signed a part-
ner agreement with the Australian Malaria Research Net-
work, on joint projects and exchange schemes, financially
supported by both the EU Commission’s Directorate
General for Research and the Australian HHMRC; EVI
(coordinating the EMVDA project), alongside EDCTP,
participates in the WHO-convened global malaria
vaccine funders group and co-funds part of their joint
activities; and ANTIMAL has engaged in a global coordi-
nation project (CRIMALDDI) where key players in
malaria drugs development, including WHO/TDR, MMV
and ANDi, (the African network for Drugs and Diagnos-
tics Innovation) intend to align research efforts for a
more rationally organized and accelerated development
of new anti-malarial drugs.
The strategic and international impact generated by
these large EU-funded malaria research consortia is to
some extent contrasted by sometimes complex adminis-
trative procedures that have to be applied to the man-
agement of projects funded with public monies, for
example when implementing dynamic elements like
competitive calls by which additional partners join an
ongoing project. Future development of funding tools
should take into account the need for dynamic changes
during the lifetime of a project.
Conclusions
A new strategic concept, brought forward at the start of
FP6, to “build ERA” in the field or malaria, was intro-
duced, tested and has shown to bear fruit. Highly active
EU-funded key consortia filled the concept with life and
built dedicated European malaria research initiatives that
have become key stakeholders in their respective fields,
both in the European and in the global context. In the
case of EU-funded malaria research, a powerful and timely
cocktail of a number of favourable factors promoted
enhanced impact of European malaria research: (1) sup-
portive political stimuli, (2) responsive programming, (3)
clear definition of the thematic area, and (4) readiness of
the targeted research community. While the general con-
cept to structure the European Research Area (ERA)
through large, strategic FP6 and FP7 projects proved gen-
erally successful in terms of generating impact and visibi-
lity, funding tools may be developed further in the spirit of
general simplification of programme management, to pro-
vide for more dynamics and flexibility in the conduct of
large strategic project efforts.
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